Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma

Annals of Oncology

Volumn 16, Issue 12, 2005, Pages 1889-1897

  Delord, J P ^a,b   Allal, C ^a   Canal, M ^a   Mery, E ^a   Rochaix, P ^a,b   Hennebelle, I ^a   Pradines, A ^a   Chatelut, E ^a,b   Bugat, R ^a,b   Guichard, S ^a,b   Canal, P ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Antineoplastic drugs; Disease free; Experimental animal models; Ovarian carcinoma; Survival; Trastuzumab

Indexed keywords

CA 125 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TOPOTECAN; TRASTUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; METASTASIS; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 28444443755     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi405     Document Type: Article

References (31)

1. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999; 91: 1113-1124.
2. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 1997; 8: 963-968.
3. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995; 332: 629-634.
4. Markman M. Role of intraperitoneal chemotherapy in the front-line setting. J Clin Oncol 2003; 21 (10 Suppl): 145-148.
5. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 2445-2459.
6. Tagliaferri P, Tassone P, Blotta S et al. Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways. Curr Drug Targets 2005; 6: 289-300.
7. Baselga J, Albanell J, Molina MA et al. Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001; 28 (5 Suppl 16): 4-11.
8. Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087-4091.
9. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244 (4905): 707-712.
10. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
11. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
12. Christianson TA, Doherty JK, Lin YJ et al. NH2-terminally truncated HER2/ neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998; 58: 5123-5129.
13. Molina MA, Codony-Servat J, Albanell J et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749.
14. Ortaldo JR, Porter HR, Miller P et al. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice. Cancer Res 1986; 46: 4414-4419.
15. Guichard S, Montazeri A, Chatelut E et al. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation. Clin Cancer Res 2001; 7: 3222-3228.
16. Treeck O, Diedrich K, Ortmann O. The activation of an extracellular signal-regulated kinase by oestradiol interferes with the effects of trastuzumab on HER2 signalling in endometrial adenocarcinoma cell lines. Eur J Cancer 2003; 39: 1302-1309.
17. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
18. Vergote I, Rustin GJ, Eisenhauer EA et al. Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000; 92: 1534-1535.
19. Vogel CL, Cobleigh MA, Tripathy D et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001; 61 (Suppl 2): 37-42.
20. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
21. Cirisano FD, Karlan BY. The role of the HER2/neu oncogene in gynecologic cancers. J Soc Gynecol Investig 1996; 3: 99-105.
22. Meden H, Marx D, Rath W et al. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: Evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994; 13: 45-53.
23. Meden H, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: A new prognostic factor. Eur J Obstet Gynecol Reprod Biol 1997; 71: 173-179.
24. Bookman MA, Darcy KM, Clarke-Pearson D et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 283-290.
25. Cuello M, Ettenberg SA, Clark AS et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001; 61: 4892-4900.
26. Le XF, Claret FX, Lammayot A et al. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 2003; 278: 23441-23450.
27. Xu F, Yu Y, Le XF et al. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER2 and HER-3 expression. Clin Cancer Res 1999; 5: 3653-3660.
28. Mohsin SK, Weiss HL, Gutierrez MC et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005; 23: 2460-2468.
29. Carson WE, Parihar R, Lindemann MJ et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 2001; 31: 3016-3025.
30. Altomare DA, Wang HQ, Skele KL et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004; 23: 5853-5857.
31. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 10983-10985.